Jiajun Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiajun Zhu has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Shelley L. Berger
University of Pennsylvania, Philadelphia, PA
7 shared publications - Craig B. Thompson
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, USA
4 shared publications Morgan A. Sammons
Epigenetics Program, Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104
4 shared publicationsZhixun Dou
Epigenetics Program, Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104
4 shared publicationsAdam M. Drake
Epigenetics Program, Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
3 shared publicationsGreg Donahue
Epigenetics Program, Department of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
3 shared publications
Latest Publications
- 23 July 2026
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 33 (8) , 1224-1235
Direct coupling of human TOM and TIM22 complexes drives mitochondrial carrier import
- 23 July 2026
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 33 (8) , 1224-1235
Direct coupling of human TOM and TIM22 complexes drives mitochondrial carrier import
- Open Access
- 1 January 2026
- Published by Science Exploration Press in Ferroptosis and Oxidative Stress
- Vol. 2 (4) , 202628
Regulation of ferroptosis by inter-organellar metabolic signaling network
Ferroptosis is a form of regulated cell death driven by iron-dependent lipid peroxidation, and is therefore intrinsically coupled to cellular redox metabolism. Progression of ferroptosis is regulated by an integrated network of metabolic signaling pathways that involve inter-organellar communication. In this Review, we synthesize recent progress in the field that has advanced our understanding of the metabolic determinants of ferroptosis. We discuss key metabolites which participate in the execution and prevention of ferroptosis, describe major signaling axes that impinge on regulating these metabolic activities to determine cellular ferroptosis sensitivity, and highlight how compartmentalized metabolism within and across distinct intracellular organelles collectively shape ferroptosis progression. Together, this Review aims to provide a framework that unifies metabolic state, signaling plasticity and organellar cooperation as a mechanistic basis of ferroptosis, underscoring its implications in the pathogenesis of various diseases including cancer.
- 1 January 2026
- Published by Science Exploration Press in Ferroptosis and Oxidative Stress
- Vol. 2 (4) , 202628
Open AccessRegulation of ferroptosis by inter-organellar metabolic signaling network
Ferroptosis is a form of regulated cell death driven by iron-dependent lipid peroxidation, and is therefore intrinsically coupled to cellular redox metabolism. Progression of ferroptosis is regulated by an integrated network of metabolic signaling pathways that involve inter-organellar communication. In this Review, we synthesize recent progress in the field that has advanced our understanding of the metabolic determinants of ferroptosis. We discuss key metabolites which participate in the execution and prevention of ferroptosis, describe major signaling axes that impinge on regulating these metabolic activities to determine cellular ferroptosis sensitivity, and highlight how compartmentalized metabolism within and across distinct intracellular organelles collectively shape ferroptosis progression. Together, this Review aims to provide a framework that unifies metabolic state, signaling plasticity and organellar cooperation as a mechanistic basis of ferroptosis, underscoring its implications in the pathogenesis of various diseases including cancer.
- 19 December 2025
- Published by Elsevier in Molecular Cell
- Vol. 85 (24) , 4587-4601.e7
The TIM22 carrier translocase supports cell proliferation by facilitating mitochondrial iron uptake for Fe-S biogenesis
- 19 December 2025
- Published by Elsevier in Molecular Cell
- Vol. 85 (24) , 4587-4601.e7
The TIM22 carrier translocase supports cell proliferation by facilitating mitochondrial iron uptake for Fe-S biogenesis
- 22 January 2024
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 35 (5) , 385-399
The redox requirement and regulation during cell proliferation
- 22 January 2024
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 35 (5) , 385-399
The redox requirement and regulation during cell proliferation
- Open Access
- 25 October 2022
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 221 (12)
mTORC1 beyond anabolic metabolism: Regulation of cell death
The mechanistic target of rapamycin complex 1 (mTORC1), a multi-subunit protein kinase complex, interrogates growth factor signaling with cellular nutrient and energy status to control metabolic homeostasis. Activation of mTORC1 promotes biosynthesis of macromolecules, including proteins, lipids, and nucleic acids, and simultaneously suppresses catabolic processes such as lysosomal degradation of self-constituents and extracellular components. Metabolic regulation has emerged as a critical determinant of various cellular death programs, including apoptosis, pyroptosis, and ferroptosis. In this article, we review the expanding knowledge on how mTORC1 coordinates metabolic pathways to impinge on cell death regulation. We focus on the current understanding on how nutrient status and cellular signaling pathways connect mTORC1 activity with ferroptosis, an iron-dependent cell death program that has been implicated in a plethora of human diseases. In-depth understanding of the principles governing the interaction between mTORC1 and cell death pathways can ultimately guide the development of novel therapies for the treatment of relevant pathological conditions.
- 25 October 2022
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 221 (12)
Open AccessmTORC1 beyond anabolic metabolism: Regulation of cell death
The mechanistic target of rapamycin complex 1 (mTORC1), a multi-subunit protein kinase complex, interrogates growth factor signaling with cellular nutrient and energy status to control metabolic homeostasis. Activation of mTORC1 promotes biosynthesis of macromolecules, including proteins, lipids, and nucleic acids, and simultaneously suppresses catabolic processes such as lysosomal degradation of self-constituents and extracellular components. Metabolic regulation has emerged as a critical determinant of various cellular death programs, including apoptosis, pyroptosis, and ferroptosis. In this article, we review the expanding knowledge on how mTORC1 coordinates metabolic pathways to impinge on cell death regulation. We focus on the current understanding on how nutrient status and cellular signaling pathways connect mTORC1 activity with ferroptosis, an iron-dependent cell death program that has been implicated in a plethora of human diseases. In-depth understanding of the principles governing the interaction between mTORC1 and cell death pathways can ultimately guide the development of novel therapies for the treatment of relevant pathological conditions.
- Top Cited Papers
- 4 February 2022
- Published by Elsevier in Cell Metabolism
- Vol. 34 (3) , 355-377
The hallmarks of cancer metabolism: Still emerging
- 4 February 2022
- Published by Elsevier in Cell Metabolism
- Vol. 34 (3) , 355-377
Top Cited PapersThe hallmarks of cancer metabolism: Still emerging
- 22 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 372 (6545) , 968-972
Mitochondrial NADP(H) generation is essential for proline biosynthesis
Providing for protein synthesis: Compartmentalization of metabolic processes into organelles can have important consequences. Zhu et al. examined the role of the coenzyme nicotinamide adenine dinucleotide phosphate (NADP + ) and its reduced form (NADPH) in cultured human cells. They found that cells lacking NAD kinase 2, an enzyme needed to make NADPH, had decreased abundance of mitochondrial NADPH and proliferated slowly in culture medium with limited nutrients because of a lack of proline. Proline is made in the mitochondria, and thus a key function of NADPH in the mitochondria appears to be the synthesis of proline to sustain cellular protein synthesis. Science , abd5491, this issue p. 968
- 22 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 372 (6545) , 968-972
Mitochondrial NADP(H) generation is essential for proline biosynthesis
Providing for protein synthesis: Compartmentalization of metabolic processes into organelles can have important consequences. Zhu et al. examined the role of the coenzyme nicotinamide adenine dinucleotide phosphate (NADP + ) and its reduced form (NADPH) in cultured human cells. They found that cells lacking NAD kinase 2, an enzyme needed to make NADPH, had decreased abundance of mitochondrial NADPH and proliferated slowly in culture medium with limited nutrients because of a lack of proline. Proline is made in the mitochondria, and thus a key function of NADPH in the mitochondria appears to be the synthesis of proline to sustain cellular protein synthesis. Science , abd5491, this issue p. 968
- Top Cited Papers
- 23 November 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (49) , 31189-31197
Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis
Significance: This work demonstrates that oncogenic activation of the PI3K-AKT-mTOR signaling pathway suppresses ferroptosis via the sterol regulatory element-binding protein-mediated lipogenesis, and that inhibition of this pathway potentiates the cancer therapeutic effect of ferroptosis induction. This finding unveils mechanisms for the regulation of ferroptosis and provides a potential cancer therapeutic approach for treating cancer patients bearing tumorigenic mutations in the PI3K-AKT-mTOR pathway.
- 23 November 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (49) , 31189-31197
Top Cited PapersOncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis
Significance: This work demonstrates that oncogenic activation of the PI3K-AKT-mTOR signaling pathway suppresses ferroptosis via the sterol regulatory element-binding protein-mediated lipogenesis, and that inhibition of this pathway potentiates the cancer therapeutic effect of ferroptosis induction. This finding unveils mechanisms for the regulation of ferroptosis and provides a potential cancer therapeutic approach for treating cancer patients bearing tumorigenic mutations in the PI3K-AKT-mTOR pathway.
- Top Cited Papers
- 11 April 2019
- Published by Springer Nature in Nature Reviews Molecular Cell Biology
- Vol. 20 (7) , 436-450
Metabolic regulation of cell growth and proliferation
Cellular metabolism is at the foundation of all biological activities. The catabolic processes that support cellular bioenergetics and survival have been well studied. By contrast, how cells alter their metabolism to support anabolic biomass accumulation is less well understood. During the commitment to cell proliferation, extensive metabolic rewiring must occur in order for cells to acquire sufficient nutrients such as glucose, amino acids, lipids and nucleotides, which are necessary to support cell growth and to deal with the redox challenges that arise from the increased metabolic activity associated with anabolic processes. Defining the mechanisms of this metabolic adaptation for cell growth and proliferation is now a major focus of research. Understanding the principles that guide anabolic metabolism may ultimately enhance ways to treat diseases that involve deregulated cell growth and proliferation, such as cancer.
- 11 April 2019
- Published by Springer Nature in Nature Reviews Molecular Cell Biology
- Vol. 20 (7) , 436-450
Top Cited PapersMetabolic regulation of cell growth and proliferation
Cellular metabolism is at the foundation of all biological activities. The catabolic processes that support cellular bioenergetics and survival have been well studied. By contrast, how cells alter their metabolism to support anabolic biomass accumulation is less well understood. During the commitment to cell proliferation, extensive metabolic rewiring must occur in order for cells to acquire sufficient nutrients such as glucose, amino acids, lipids and nucleotides, which are necessary to support cell growth and to deal with the redox challenges that arise from the increased metabolic activity associated with anabolic processes. Defining the mechanisms of this metabolic adaptation for cell growth and proliferation is now a major focus of research. Understanding the principles that guide anabolic metabolism may ultimately enhance ways to treat diseases that involve deregulated cell growth and proliferation, such as cancer.
- 17 August 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (35) , 9822-9827
Lysine methylation represses p53 activity in teratocarcinoma cancer cells
TP53 (which encodes the p53 protein) is the most frequently mutated gene among all human cancers, whereas tumors that retain the wild-type TP53 gene often use alternative mechanisms to repress the p53 tumor-suppressive function. Testicular teratocarcinoma cells rarely contain mutations in TP53, yet the transcriptional activity of wild-type p53 is compromised, despite its high expression level. Here we report that in the teratocarcinoma cell line NTera2, p53 is subject to lysine methylation at its carboxyl terminus, which has been shown to repress p53’s transcriptional activity. We show that reduction of the cognate methyltransferases reactivates p53 and promotes differentiation of the NTera2 cells. Furthermore, reconstitution of methylation-deficient p53 mutants into p53-depleted NTera2 cells results in elevated expression of p53 downstream targets and precocious loss of pluripotent gene expression compared with re-expression of wild-type p53. Our results provide evidence that lysine methylation of endogenous wild-type p53 represses its activity in cancer cells and suggest new therapeutic possibilities of targeting testicular teratocarcinoma. Significance Cancer progression typically involves inactivation of the p53 tumor suppressor. In testicular teratocarcinoma, there exist unusually high protein levels of wild-type p53, but strikingly, without normal activation of genes up-regulated by p53, such as cell cycle arrest and DNA repair pathways. This suggests that posttranslational mechanisms, such as protein modification, may repress activity of the high levels of wild-type p53. Our findings demonstrate an important role in teratocarcinoma of previously characterized repressive p53 methylation, which down-regulates normal p53 activation functions. The results suggest the potential for novel approaches to reactivate wild-type p53 in teratocarcinoma via therapeutic inhibition of the methyltransferase enzymes that modify p53, which could be similarly appropriate for treatment of other cancers expressing high levels of wild-type p53.
- 17 August 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (35) , 9822-9827
Lysine methylation represses p53 activity in teratocarcinoma cancer cells
TP53 (which encodes the p53 protein) is the most frequently mutated gene among all human cancers, whereas tumors that retain the wild-type TP53 gene often use alternative mechanisms to repress the p53 tumor-suppressive function. Testicular teratocarcinoma cells rarely contain mutations in TP53, yet the transcriptional activity of wild-type p53 is compromised, despite its high expression level. Here we report that in the teratocarcinoma cell line NTera2, p53 is subject to lysine methylation at its carboxyl terminus, which has been shown to repress p53’s transcriptional activity. We show that reduction of the cognate methyltransferases reactivates p53 and promotes differentiation of the NTera2 cells. Furthermore, reconstitution of methylation-deficient p53 mutants into p53-depleted NTera2 cells results in elevated expression of p53 downstream targets and precocious loss of pluripotent gene expression compared with re-expression of wild-type p53. Our results provide evidence that lysine methylation of endogenous wild-type p53 represses its activity in cancer cells and suggest new therapeutic possibilities of targeting testicular teratocarcinoma. Significance Cancer progression typically involves inactivation of the p53 tumor suppressor. In testicular teratocarcinoma, there exist unusually high protein levels of wild-type p53, but strikingly, without normal activation of genes up-regulated by p53, such as cell cycle arrest and DNA repair pathways. This suggests that posttranslational mechanisms, such as protein modification, may repress activity of the high levels of wild-type p53. Our findings demonstrate an important role in teratocarcinoma of previously characterized repressive p53 methylation, which down-regulates normal p53 activation functions. The results suggest the potential for novel approaches to reactivate wild-type p53 in teratocarcinoma via therapeutic inhibition of the methyltransferase enzymes that modify p53, which could be similarly appropriate for treatment of other cancers expressing high levels of wild-type p53.